Clinical Trials

345 enrolled 11 charts

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

605 enrolled 14 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

291 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT03221426 2026-03-09

KEYNOTE-585

1,007 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 3 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

120 enrolled 17 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

403 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT04471428 2025-12-22

CONTACT-01

366 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT00309985 2025-12-11

CHAARTED

790 enrolled 11 charts

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 5 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 2 FDA

Breast Neoplasms

NCT01933932 2025-11-19

SELECT-1

510 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03906071 2025-10-21

SAPPHIRE

577 enrolled 22 charts

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT00532155 2025-09-10

VITAL

913 enrolled 16 charts

Carcinoma, Lung Neoplasms

NCT03976375 2025-08-15

LEAP-008

422 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

315 enrolled 11 charts

Breast Neoplasms

NCT04154956 2025-08-05

CARMEN-LC03

389 enrolled 16 charts

Non-small Cell Lung Cancer Metastatic

NCT02975934 2025-07-25

TRITON3

405 enrolled 34 charts 3 FDA

Metastatic Castration Resistant Prostate Cancer

NCT03834506 2025-07-18

KEYNOTE-921

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

3,270 enrolled 16 charts

Breast Neoplasms

NCT04921358 2025-06-29

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

377 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT05089734 2025-05-23

EVOKE-01

603 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT04427072 2025-05-16

GeoMETry-III

22 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT02288247 2025-04-08

PRESIDE

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00667251 2025-03-21

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

652 enrolled 50 charts

Breast Neoplasms

NCT00446225 2025-03-05

EURTAC

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00324805 2025-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

1,501 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02231164 2025-02-13

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

12 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT02908477 2025-02-11

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

228 enrolled 12 charts

Head & Neck

Oropharyngeal Neoplasms

NCT03358875 2025-02-10

RATIONALE-303

805 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT01828112 2025-02-07

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

231 enrolled 33 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04685135 2025-01-22

KRYSTAL-12

453 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00478699 2024-12-12

GECP-SCAT

500 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT02613507 2024-11-19

CheckMate 078

504 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03430843 2024-10-26

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

512 enrolled 27 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT02864394 2024-09-19

MK-3475-033

425 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

214 enrolled 16 charts

HER2-positive Breast Cancer

NCT04907227 2024-07-12

KEYNOTE-921

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

108 enrolled 7 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 3 FDA